The inability to observe RUNX2 deletion in bone metastases from public datasets despite the reproducible presence of RUNX2 loss in CTCs from men with bone metastases may reflect tumor heterogeneity, stromal contamination, or differences in detection sensitivity due to probe coverage of the RUNX2 gene. This evidence concerns the gene RUNX2 and neoplasm.